Hepatorenal syndrome is a type of kidney failure that occurs in people with advanced liver disease, most often cirrhosis. The kidneys themselves aren’t damaged. Instead, severe changes in blood flow caused by the failing liver starve the kidneys of the circulation they need to work. Without treatment, the most acute form carries a median survival of roughly 11 days, making it one of the most serious complications of end-stage liver disease.
How Liver Disease Causes Kidney Failure
In advanced cirrhosis, scar tissue blocks normal blood flow through the liver, creating high pressure in the portal vein (the large vessel that carries blood from the gut to the liver). The body compensates by widening blood vessels in the abdomen and elsewhere, a process called splanchnic vasodilation. While those vessels relax and expand, the total volume of blood doesn’t increase to match, so the body enters a state of “relative” low blood volume even though no blood has actually been lost.
Sensing that drop in effective circulation, the body activates several emergency systems at once: the sympathetic nervous system (fight-or-flight), the hormone cascade that controls blood pressure and salt balance (renin-angiotensin-aldosterone), and antidiuretic hormone, which signals the kidneys to hold onto water. These systems tell the kidneys to retain sodium and fluid in an attempt to refill the circulation. Over time, though, the kidneys themselves receive less and less blood flow. Eventually they can no longer filter waste effectively, and kidney function declines rapidly, even though the kidney tissue itself remains structurally intact.
Common Triggers
Hepatorenal syndrome rarely appears out of nowhere. It usually follows a specific event that tips the already fragile circulatory balance. The most common triggers are bacterial infection of the abdominal fluid (spontaneous bacterial peritonitis), large-volume drainage of abdominal fluid without replacing plasma volume afterward, and gastrointestinal bleeding. About one-third of patients who develop spontaneous bacterial peritonitis go on to develop hepatorenal syndrome. Any severe infection, aggressive use of diuretics, or sudden worsening of liver function can also set it off.
Two Forms of the Condition
Clinicians now classify hepatorenal syndrome based on how quickly kidney function deteriorates. The more dangerous form, called HRS-AKI (acute kidney injury), involves a rapid rise in waste products in the blood. Historically this was defined as a doubling of creatinine to above 2.5 mg/dL within two weeks. Updated criteria from the International Club of Ascites define it more broadly: a creatinine increase of at least 0.3 mg/dL within 48 hours or a 50% rise from baseline within seven days. If no recent blood work exists, a value from the previous three months can serve as the baseline.
The slower form, previously called type 2, involves a more gradual decline in kidney function. It typically shows up alongside resistant fluid buildup in the abdomen (ascites that no longer responds to diuretics). Patients with this slower form have a median survival of about six months, significantly longer than the acute form but still a sign of very advanced disease.
How It’s Diagnosed
Hepatorenal syndrome is a diagnosis of exclusion, meaning doctors must rule out every other reason the kidneys might be failing before confirming it. The current diagnostic criteria require all of the following: confirmed cirrhosis with ascites, kidney injury that meets the thresholds above, no improvement after stopping diuretics and giving intravenous albumin for two consecutive days, no shock, no recent use of drugs that can damage the kidneys (such as certain anti-inflammatory painkillers or contrast dyes used in imaging), and no signs of structural kidney disease on ultrasound or urine tests.
That albumin challenge is a key step. Many patients with cirrhosis develop kidney problems simply because they’re dehydrated or have lost fluid volume. If the kidneys bounce back after fluid replacement, it’s not hepatorenal syndrome. Only when kidney function fails to recover despite adequate volume does the diagnosis apply.
Treatment Options
The first-line medical treatment combines a drug that constricts the widened abdominal blood vessels (terlipressin) with intravenous albumin at doses of 20 to 40 grams per day. The idea is to redirect blood flow back toward the kidneys by squeezing those dilated splanchnic vessels while simultaneously expanding blood volume. Response to this therapy makes a dramatic difference: patients who respond have a median survival of about 29 months, compared to roughly 8 months for those who don’t.
For patients who aren’t candidates for these medications or don’t respond, a procedure called TIPS (transjugular intrahepatic portosystemic shunt) may be considered. This involves placing a small channel inside the liver to relieve portal pressure and improve circulation. However, TIPS carries its own risks, particularly for patients with very advanced liver disease. A scoring system called MELD, which factors in creatinine, bilirubin, and blood clotting, helps predict outcomes: scores above 18 are associated with significantly higher mortality within three months of the procedure. TIPS is also not an option for patients with heart failure, severe infection, advanced confusion from liver-related brain dysfunction, or certain liver cancers.
Liver Transplant and Long-Term Outlook
A liver transplant is the only definitive treatment. Because hepatorenal syndrome is driven by the failing liver rather than by kidney disease, replacing the liver can, in theory, allow the kidneys to recover completely. In practice, the results are more nuanced. One study tracking patients with the acute form found that kidney function recovered in 58% of cases after transplant, defined as remaining off dialysis with creatinine below 1.5 mg/dL. The remaining patients had persistent kidney problems, and some required ongoing dialysis.
The likelihood of full kidney recovery depends partly on how long the kidneys were impaired before transplant. Prolonged kidney failure can eventually cause structural damage that doesn’t reverse, even after the liver is replaced. This is one reason early recognition matters so much: the sooner hepatorenal syndrome is identified and treated, the better the chances that kidney function can be preserved long enough to reach transplant.
Why Early Recognition Matters
Hepatorenal syndrome sits at the end of a long chain of circulatory changes that begin early in cirrhosis. By the time kidney function drops, the underlying circulation is already severely compromised. The window between onset and irreversible decline is narrow, especially in the acute form. Any patient with cirrhosis and ascites who notices a sudden drop in urine output, new or worsening swelling, confusion, or rapidly increasing fatigue should be evaluated urgently. Infections, even ones that seem mild, can be the tipping point, so unexplained fever or abdominal pain in someone with known liver disease warrants immediate attention.